Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

The phosphodiesterase inhibitory selectivity and the in vitro and in vivo potency of the new PDE5 inhibitor vardenafil.

Saenz de Tejada I, Angulo J, Cuevas P, Fernández A, Moncada I, Allona A, Lledó E, Körschen HG, Niewöhner U, Haning H, Pages E, Bischoff E.

Int J Impot Res. 2001 Oct;13(5):282-90.

PMID:
11890515
2.

Overview of phosphodiesterase 5 inhibition in erectile dysfunction.

Rosen RC, Kostis JB.

Am J Cardiol. 2003 Nov 6;92(9A):9M-18M. Review.

PMID:
14609619
3.

Phosphodiesterase type 5 as a pharmacologic target in erectile dysfunction.

Corbin JD, Francis SH, Webb DJ.

Urology. 2002 Sep;60(2 Suppl 2):4-11. Review.

PMID:
12414329
4.

The pharmacology of sildenafil, a novel and selective inhibitor of phosphodiesterase (PDE) type 5.

Wallis RM.

Nihon Yakurigaku Zasshi. 1999 Oct;114 Suppl 1:22P-26P. Review.

PMID:
10629850
5.

Vardenafil preclinical trial data: potency, pharmacodynamics, pharmacokinetics, and adverse events.

Bischoff E.

Int J Impot Res. 2004 Jun;16 Suppl 1:S34-7. Review.

PMID:
15224134
6.

Mechanisms of action of PDE5 inhibition in erectile dysfunction.

Corbin JD.

Int J Impot Res. 2004 Jun;16 Suppl 1:S4-7. Review.

PMID:
15224127
7.

Potency, selectivity, and consequences of nonselectivity of PDE inhibition.

Bischoff E.

Int J Impot Res. 2004 Jun;16 Suppl 1:S11-4. Review.

PMID:
15224129
8.
9.

Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions.

Kloner RA.

Am J Cardiol. 2005 Dec 26;96(12B):42M-46M. Epub 2005 Dec 5. Review.

PMID:
16387566
10.

Vardenafil: a novel type 5 phosphodiesterase inhibitor for the treatment of erectile dysfunction.

Kendirci M, Bivalacqua TJ, Hellstrom WJ.

Expert Opin Pharmacother. 2004 Apr;5(4):923-32. Review.

PMID:
15102574
11.
12.

Sildenafil citrate, a selective phosphodiesterase type 5 inhibitor: urologic and cardiovascular implications.

Nehra A, Colreavy F, Khandheria BK, Chandrasekaran K.

World J Urol. 2001 Feb;19(1):40-5. Review.

PMID:
11289569
13.

Vardenafil.

Young JM.

Expert Opin Investig Drugs. 2002 Oct;11(10):1487-96. Review.

PMID:
12387708
14.

PDE-5 inhibition and sexual response: pharmacological mechanisms and clinical outcomes.

Rosen RC, McKenna KE.

Annu Rev Sex Res. 2002;13:36-88. Review.

PMID:
12836729
15.
16.

Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease.

Ravipati G, McClung JA, Aronow WS, Peterson SJ, Frishman WH.

Cardiol Rev. 2007 Mar-Apr;15(2):76-86. Review.

PMID:
17303994
17.

Phosphodiesterase inhibitors for the treatment of erectile dysfunction.

Küthe A, Montorsi F, Andersson KE, Stief CG.

Curr Opin Investig Drugs. 2002 Oct;3(10):1489-95. Review.

PMID:
12431025
18.

Rabbits as models for impotence research.

Bischoff E.

Int J Impot Res. 2001 Jun;13(3):146-8. Review.

PMID:
11525311
19.

Vardenafil treatment for erectile dysfunction.

Crowe SM, Streetman DS.

Ann Pharmacother. 2004 Jan;38(1):77-85. Review.

PMID:
14742800
20.
Items per page

Supplemental Content

Write to the Help Desk